Seasonal Influenza vaccine

ApprovedVaccine

Novartis

Seasonal Influenza vaccine is one of 83 biologic programs targeting Multiple Sclerosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple SclerosisActive, not recruiting

InfluenzaActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Pneumococcal VaccinesActive, not recruiting

Multiple SclerosisPhase 3

Active, not recruiting

InfluenzaPhase 3

Active, not recruiting

Chronic Kidney DiseaseApproved

Active, not recruiting

Pneumococcal VaccinesPhase 3

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Seasonal Influenza vaccine

Novartis

Approved

22 2

Fluzone

Sanofi

Preclinical

16 3

Fluzone

GSK

Preclinical

37 4

Trexall

Alnylam Pharmaceuticals

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 10

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Pneumococcal Vaccines

NCT07365826

Q2 2027

Active, not recruiting

BRCA1 Mutation

NCT04499534

Q1 2028

Post-ApprovalRecruiting

Influenza

NCT05108818

Clinical

Trials by Indication[1]

Influenza22 trials

Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2018)

Completed·BButantan Institute··NCT03392207·403 enrolled

Two-site Intradermal Influenza Vaccination in Elderly

Completed·QQueen Saovabha Memorial Institute·N/A·NCT01202552·180 enrolled

Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects

Completed· Novartis logo

Novartis·Phase 2·NCT01357265·125 enrolled

Show 19 more trials

Heterologous Effect of Diptheria, Tetanus, Acellular Pertussis Vaccination on Influenza Challenge in the Elderly

Unknown status·CClifford Craig Medical Research Trust·N/A·NCT02765126·450 enrolled

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects

Completed· Novartis logo

Novartis·Phase 2·NCT00956449·126 enrolled

Persistence of Immune Response After Vaccination With Influenza Vaccine

Completed·CCenters for Disease Control and Prevention, China·N/A·NCT01906190·207 enrolled

Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine

Completed·PPantec Biosolutions AG·Phase 1·NCT02988739·20 enrolled

Seasonal Influenza Vaccine Effectiveness Study in Kenya

Completed·GGideon Emukule··NCT01432340·10,000 enrolled

Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009

Completed· Novartis logo

Novartis·Phase 2·NCT00734734·64 enrolled

Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine

Completed·AAlachua Government Services, Inc.·Phase 3·NCT01063088·211 enrolled

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

Recruiting·UUniversity of Pennsylvania·Phase 4·NCT05108818·700 enrolled

A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus

Completed· Inovio Pharmaceuticals logo

Inovio Pharmaceuticals·Phase 1·NCT01405885·116 enrolled

Improved Novel VaccIne CombinaTion InflUenza Study

Terminated·BBarinthus Biotherapeutics·Phase 2·NCT03300362·862 enrolled

Active Surveillance for Adverse Events Following Immunization With the Influenza Vaccine Produced at Butantan Institute

Completed·BButantan Institute··NCT03057483·533 enrolled

Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010

Completed· Novartis logo

Novartis·Phase 2·NCT00956761·63 enrolled

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012

Completed· Novartis logo

Novartis·Phase 2·NCT01344057·63 enrolled

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009

Completed· Novartis logo

Novartis·Phase 3·NCT00735410·134 enrolled

Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects

Completed· Novartis logo

Novartis·Phase 3·NCT01422512·126 enrolled

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

Completed·EEmory University·Phase 4·NCT03701061·12 enrolled

Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers

Unknown status·IIsconova AB·Phase 1·NCT01444482·110 enrolled

Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 4·NCT01980836·40 enrolled

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month

Unknown status·CCenters for Disease Control and Prevention, China·Phase 3·NCT01040078·900 enrolled

Multiple Sclerosis2 trials

Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)

Completed· Novartis logo

Novartis·Phase 3·NCT01199861·138 enrolled

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT05028634·63 enrolled

Vaccine Response1 trial

MTX Discontinuation and Vaccine Response

Completed·SSeoul National University Hospital·Phase 4·NCT02748785·277 enrolled

Immune Response1 trial

Effect of Drinking Fermented Milk on Immune Response

Completed·MMahidol University·N/A·NCT02909842·60 enrolled

Chronic Kidney Disease1 trial

The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis

Unknown status·NNational Cheng-Kung University Hospital·Phase 4·NCT02105519·200 enrolled

3 more indications

BRCA1 Mutation1 trial

Influenza Vaccine Study in BRCA1 or BRCA2 Carriers

Active, not recruiting·AAbramson Cancer Center at Penn Medicine··NCT04499534·50 enrolled

Pneumococcal Vaccines1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 Concomitantly Administered With Seasonal Influenza Vaccine in Healthy Subjects 50 Years of Age and Older

Active, not recruiting·VVaxcyte, Inc.·Phase 3·NCT07365826·1,390 enrolled

Unspecified1 trial

Fasting-mimicking Diet and Immunosenescence

Withdrawn·UUniversity of Southern California·Phase 2·NCT02554188

Sources

References

[1]
ClinicalTrials.gov — 30 trial records for Seasonal Influenza vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Seasonal Influenza vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Seasonal Influenza vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: Novartis

Seasonal Influenza vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q1 2028

Trials by Indication[1]

Influenza22 trials

Multiple Sclerosis2 trials

Vaccine Response1 trial

Immune Response1 trial

Chronic Kidney Disease1 trial

BRCA1 Mutation1 trial

Pneumococcal Vaccines1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News